IAS 2025, 13th IAS Conference on HIV Science Kigali, Rwanda July 13-17

Conference Reports for NATAP


IAS 2025, 13th IAS Conference on HIV Science Kigali, Rwanda July 13-17

	Evaluation of differences in online drug-drug interaction tools among adults living with HIV - (07/26/25) Association between cognitive performance and subclinical atherosclerosis among older adults with HIV: a cross-sectional evaluation from ELEA-Brasil Study - (07/26/25) Shorter telomere lengths and faster telomere attrition rates are associated with unsuppressed viraemia and lower CD4 count in antiretroviral-treated adolescents with perinatally-acquired HIV from Zambia and Zimbabwe - (07/26/25) Exploring the relationship between dolutegravir and diabetes using programmatic data in a cohort of ART clients in Lubombo and Manzini - (07/25/25) Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial - (07/25/25) bNAb immunotherapy and HIV remission: Insights from the PAUSE (Pausing Antiretroviral Treatment Under Structured Evaluation) trial - (07/25/25) PedMAb1 trial: safety of two broadly neutralising antibodies, CAP256V2LS and VRC07-523LS, administered singly or concurrently at birth and 3 months to breastfeeding HIV-1 exposed neonates and infants born without HIV - (07/25/25) Recurrent falls as a marker for frailty in virologically suppressed PLWH in Salvador, Brazil: 17% Falls Prevalence, 5.4% Recurrent Falls: 52 Age - (07/25/25) Prevalence, Incidence, and Risk Factors for Dermatologic Conditions in People with HIV in the Modern Antiretroviral Era: A Cohort Study in Washington, DC - (07/25/25) Perspectives of People With HIV-1 24 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-world US Study (BEYOND) - (07/22/25) 24-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study - (07/22/25) PrEP experiences and challenges among transgender women in the United States and Puerto Rico in the era of PrEP choice: findings from the ENCORE cohort - (07/22/25) Real-world Utilization and Adherence of Cabotegravir Long-Acting for HIV Pre-Exposure Prophylaxis in the United States: Results From the PrEPFACTS Study Using Healthcare Administrative Claims Data - (07/22/25) Choices in motion: How young people in the PrEPared to Choose study (Cape Town, South Africa) navigate PrEP product switching - (07/22/25) First experience of dual antiretroviral maintenance regimen in West and Central Africa compared with continuing 3-drug current antiretroviral regimens (CARs): week 96 results from the MODERATO trial (ANRS -MIE 12372) - (07/20/25) Promising new therapeutic option for HIV - next generation HIV-1 investigational protease cleavage site (maturation) inhibitor, HRF-10071 - phase 2 results - (07/20/25) Is long-acting injectable antiretroviral therapy safe in countries with high hepatitis B prevalence?: insights from the IMPALA study ? - (07/20/25) MK-8527 Monthly PrEP Phase 3 Studies, In Lactating Women - (07/20/25) Ageing with HIV at IAS - (07/20/25) Plans for MK-8527-07 - (07/19/25) CAB PrEP: Updates on evaluation of CAB-LA Safety During Pregnancy - (07/19/25) Pregnancy and neonatal outcomes following prenatal exposure to cabotegravir (CAB): data from The Antiretroviral Pregnancy Registry (APR) - (07/19/25) Pregnancy with PURPOSE - (07/19/25) Lenacapavir dosing in special situations: Tuberculosis and beyond - (07/19/25) Inclusion of pregnant and lactating people in the PURPOSE 1 study: efficacy, safety, and pharmacokinetics - (07/19/25) Preference for twice-yearly injections vs daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men, and gender nonbinary people enrolled in PURPOSE 2 - (07/19/25) Efficacy, safety, and pharmacokinetics of twice-yearly subcutaneous lenacapavir for PrEP among adolescents and young people in the phase 3 trials PURPOSE 1 and PURPOSE 2 - (07/19/25) Estimation of the Counterfactual HIV Incidence in the PURPOSE Trials - (07/19/25) Safety and Pharmacokinetics of MK-8527 Oral Once-Monthly: A Phase 2 Study in Adults at Low Risk of HIV-1 Exposure, oral - (07/19/25) Antiretroviral Therapy (ART): What's New - (07/18/25) Altered viral rebound dynamics in chronically treated people with HIV given long-acting broadly neutralizing antibodies and N-803 - (07/18/25) ART Drug Interactions, herbals, LEN, INSTIs, LA - (07/18/25) Systemic Review and Meta-Analysis of the Efficacy of Intermittent Antiretroviral Therapy dosing: a crisis response to the sudden cuts in USAID and PEPFAR funding - (07/18/25) Modelling the impact of cuts in PEPFAR funding for HIV pre-exposure prophylaxis among key populations in sub-Saharan Africa - (07/18/25) Short cycle antiretroviral therapy (ART) with weekends off is inferior to continuous ART in adolescents living with HIV receiving tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) in sub-Saharan Africa: BREATHER Plus 96-week results - (07/18/25) Long-acting cabotegravir and rilpivirine in adults with suboptimal HIV control in sub-Saharan Africa: the IMPALA trial 48-week results - (07/18/25) Liraglutide for obesity in HIV (LIROH): a clinical trial evaluating acceptability, impact on cardiometabolic risks & gut immunity of GLP-1 receptor agonists in South Africa: gut CD4 recovery - (07/18/25) Topical trichloroacetic acid versus electrocautery for the treatment of anal intraepithelial neoplasia in patients living with HIV: a multicentre randomized non-inferiority trial - (07/18/25) A Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Extended Multiple Dosing of Ulonivirine (MK-8507) in Adults Without HIV - (07/18/25) Safety and pharmacokinetics of MK-8527 oral once-monthly: a phase 2 study in adults at low risk of HIV-1 exposure - (07/18/25) Long-acting ART (LEN/CAB and CAB/RPV) among viremic persons living with HIV - (07/18/25) Safety and Pharmacokinetics of MK-8527 Oral Once-Monthly: A Phase 2 Study in Adults at Low Risk of HIV-1 Exposure, oral - (07/18/25) One-Year Implementation Outcomes of Cabotegravir Long-Acting Injectable PrEP in Men Who Have Sex With Men (MSM) & Transgender Men (TGM): Findings From the PILLAR Study - (07/18/25) Health Care Provider Experiences After 12 Months of Implementing Cabotegravir Long-Acting Injectable PrEP (CAB LA) for Black Women: EBONI Study Results - (07/18/25) Factors Impacting Women's Choice of PrEP Product After the Randomized Blinded Phase of PURPOSE 1 - (07/18/25) Exploratory Qualitative Analysis of the Acceptability of HIV Prevention Methods Among Pregnant Women and Lactating Women Interviewed During the Randomized Blinded Phase of PURPOSE 1 - (07/18/25) Predictors of HIV Pre-Exposure Prophylaxis Preferences Using the Health Belief Model: Twice-Yearly Subcutaneous Lenacapavir Versus Daily Pills in the PURPOSE 1 Trial - (07/18/25) Indirect Treatment Comparison of the Efficacy of Cabotegravir and Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) Versus No PrEP and Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) - (07/18/25) Comorbidities PWH vs HIV- Africa - (07/18/25) Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once-Daily Maintained Viral Suppression in the Presence of Archived M184I/V Resistance-Associated Mutations in Proviral DNA - (07/18/25) HIV-Specific T Cell Responses in Virologically Suppressed PWH Receiving Lenacapavir, Teropavimab, and Zinlirvimab - (07/18/25) ACTG A5391: A Randomized Multicenter 3-arm Controlled Trial for People with Obesity on Integrase Inhibitors and Tenofovir Alafenamide switching to Doravirine, with or without Tenofovir Disoproxil Fumarate (The DO-IT Trial) - (07/18/25) Predictors of Weight Gain Among People with HIV over 3-Year Period - (07/18/25) Real-world Effectiveness of CAB+RPV LA in Individuals with HIV Viremia at Therapy Initiation - (07/18/25) A Double-Blind, Active-Controlled, Phase 2b Study to Evaluate the Efficacy and Safety of Ulonivirine in Combination With Islatravir in Virologically Suppressed Adults Living With HIV-1 - (07/18/25) High Virologic Suppression and few Virologic Failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe - (07/18/25) Vesatolimod Pharmacodynamic Responses in a Trial of Vesatolimod and Broadly Neutralizing Antibodies in Early-Treated South African Women With Clade C HIV-1 - (07/18/25) Clinical outcomes among women in the OPERA Cohort initiating CAB+RPV LA with viral loads > 50 copies/mL - (07/18/25) Clinical Outcomes at Month 24 After Initiation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (07/18/25) The Power of Choice: Strong Preference for CAB+RPV LA Following Rapid Suppression With DTG/3TC in ART-Naive People Living With HIV - (07/18/25) ViiV HEALTHCARE EXTENDS VOLUNTARY LICENSING AGREEMENT WITH MEDICINES PATENT POOL TO ENABLE ACCESS TO INNOVATIVE LONG-ACTING INJECTABLE HIV TREATMENT - (07/18/25) Phase 2 Once-Weekly Dose Optimization for Ulonivirine in Combination with Islatravir 2 mg - (07/18/25) An Open-Label Phase 1 Study to Evaluate Drug Interactions Between Multiple Weekly Doses of Ulonivirine (MK-8507) and Single Doses of Islatravir in Adults Without HIV - (07/18/25) A Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Extended Multiple Dosing of Ulonivirine (MK-8507) in Adults Without HIV - (07/18/25)